Phase I Study of CS-7017 and Bexarotene

Inclusion Criteria

• •Histologically proven advanced malignancy with measurable disease except for acute leukemias
• •Progression on, or intolerance of, or ineligibility for all standard therapies
• •Biopsy accessible tumor deposits
• •LVEF \>/= institutional normal
• •No evidence of clinically significant fluid retention
• •ECOG Performance status 0-2
• •Subjects with no brain metastases or a history of previously treated brain metastases who have been treated with surgery or stereotactic radiosurgery at least 4 weeks prior to enrollment and have a baseline MRI that shows no evidence of intracranial disease and have not had treatment with steroids within one week of study enrollment.
• •Adequate hepatic, bone marrow, and renal function
• •Partial thromboplastin time must be \</= 1.5 x upper limit of normal range and INR \< 1.5. Subjects on anticoagulant will be permitted to enroll as long as the INR is in the acceptable therapeutic range
• •Life expectancy \> 12 weeks
• •Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
• •Subject is capable of understanding and complying with parameters of the protocol and able to sign and date the informed consent.
• •Active severe infection or known chronic infection with HIV or hepatitis B virus
• •Cardiovascular disease including unstable angina, therapy for life-threatening ventricular arrhythmia, or myocardial infarction, stroke or congestive heart failure within the last 6 months
• •Life-threatening visceral disease or other severe concurrent disease
• •Women who are pregnant or breastfeeding
• •Anticipated survival under 3 months
• •Clinically significant and uncontrolled major medical condition(s)